Given the critical role of AMPK in regulating NAFLD, our findings suggest that targeting the deacetylation of LKB1 by tranilast represents a promising therapeutic strategy for metabolic liver diseases. This evidence concerns the gene STK11 and metabolic dysfunction-associated steatotic liver disease.